Low Prevalence of Risk Markers in Cases of Sudden Death Due to Brugada Syndrome Relevance to Risk Stratification in Brugada Syndrome by Raju, Hariharan et al.
Journal of the American College of Cardiology Vol. 57, No. 23, 2011
© 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00Low Prevalence of Risk Markers in Cases of Sudden
Death Due to Brugada Syndrome
Relevance to Risk Stratification in Brugada Syndrome
Hariharan Raju, MBCHB,* Michael Papadakis, MBBS,* Malini Govindan, B MED,*
Rachel Bastiaenen, MBBS,* Navin Chandra, MBBS,* Ann O’Sullivan, BSC,† Georgina Baines, BSC,‡
Sanjay Sharma, MBCHB, MD,* Elijah R. Behr, MBBS, MD*
London and Oxford, United Kingdom
Objectives The objective of this study was to determine the prevalence of conventional risk factors in sudden arrhythmic
death syndrome (SADS) probands with Brugada syndrome (BrS).
Background Patients with BrS and previous aborted sudden cardiac death (SCD) are at high risk of recurrent events. Other
universally accepted clinical features associated with higher risk include unheralded syncope and the presence
of a spontaneous type 1 electrocardiogram (ECG).
Methods We analyzed reported symptoms and reviewed ECGs from SADS probands with familial diagnoses of BrS, estab-
lished by cardiological evaluation, including ECG, 2-dimensional echocardiography, Holter monitoring, exercise
tolerance testing, and ajmaline provocation. These cases underwent familial evaluation between 2003 and
2010.
Results A total of 49 consecutive families with a confirmed SADS death and a diagnosis of BrS were evaluated, compris-
ing assessment of 202 family members in total. One family had 2 members with SADS, resulting in a total of 50
probands included. Mean age of death of probands was 29.1  10.6 years, with 41 males (82%) (p  0.05).
Antemortem ECGs were available for 5 SADS probands, 1 of which demonstrated a spontaneous type 1 pattern.
In 45 probands, symptoms before death were reported reliably by family members. Of these, 9 (20%) had expe-
rienced at least 1 syncopal episode before the fatal event. Importantly, 68% of probands would not have fulfilled
any current criteria for consideration of implantable cardioverter-defibrillator.
Conclusions The “low-risk” asymptomatic BrS group comprises the majority of SCD in this cohort. Current risk stratification
would appear to be inadequate, and new markers of risk are vital. (J Am Coll Cardiol 2011;57:2340–5)
© 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.067Brugada syndrome (BrS) is a primary electrical disease that
predisposes those affected to life-threatening ventricular
arrhythmias, which are predominantly nocturnal (1). De-
spite its recent introduction as a clinical entity (2), BrS has
an established genetic etiology related predominantly to
cardiac sodium channel dysfunction in 20% of cases and
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accepted November 9, 2010.demonstrates an autosomal dominant inheritance pattern
(3). Nevertheless, BrS remains characterized by stereotypi-
cal electrocardiographic (ECG) findings in affected patients
(1), in combination with clinical or familial history. How-
ever, in some patients, ECG changes can fluctuate between
normal and the Brugada pattern (4); hence, provocation
testing with a class I antidysrhythmic, such as ajmaline, is
used to unmask the BrS phenotype in suspected cases (5–8).
Patients with BrS who have survived a ventricular fibrilla-
tion arrest are recommended to receive an implantable
cardioverter-defibrillator (ICD) in light of the significant
risk of recurrent events (1,9). The other recognized high-
risk group recommended for an ICD consists of patients
with symptoms secondary to a presumed self-terminating
malignant arrhythmia in the presence of a type 1 Brugada
ECG (10,11). A number of studies have evaluated the
additional value of specialist ECG and invasive assessments
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impact have been inconsistent (9–13). We report on a
retrospectively analyzed cohort of individuals who experi-
enced unexplained sudden death, with a diagnosis of BrS
established following familial evaluation (14,15), with re-
gard to the prevalence of these high-risk characteristics.
Methods
Study cohort. This study represents unselected, consecu-
tive, familial diagnoses of BrS from 3 tertiary referral centers
in the United Kingdom, in the context of unexplained
familial sudden cardiac death (SCD). Data from clinical
evaluations of the blood relatives of individuals who expe-
rienced sudden arrhythmic death syndrome (SADS) re-
ferred between 2003 and 2010 to specialist inherited cardiac
disease clinics at Lewisham University, King’s College, and
St. George’s Hospitals (London) were retrospectively re-
viewed. All SADS probands with at least 1 blood relative
diagnosed with BrS were included.
Cardiological evaluation. An evaluation protocol for fam-
lies with a member with SADS has been established (Fig. 1),
ith particular emphasis on evaluation for evidence of
amilial BrS. All family members were investigated with
Figure 1 Investigational Cascade for SADS Probands and Their
A summary of the investigation undertaken following referral of a family of an indiv
establishing a familial diagnosis of Brugada syndrome (BrS). ECG  electrocardiogclinical history and noninvasive
evaluation by ECG, transtho-
racic echocardiography (includ-
ing close evaluation of the right
ventricle), Holter ambulatory
monitoring, and stress testing,
with additional magnetic reso-
nance imaging to exclude struc-
tural heart disease.
Genetic testing. Following ap-
propriate genetic counseling, we
offered sodium channel, voltage-
gated, type V, alpha subunit
(SCN5A) mutation analysis to
family members with a clinical
diagnosis of BrS.
Ajmaline provocation test. Ajmaline provocation was per-
formed with 1 mg/kg intravenous ajmaline administered
over 5 min, with real-time ECG monitoring and ECGs
recorded for analysis at 10- to 30-s intervals for 15 min from
the start of ajmaline administration or until return of the
ECG to baseline. Before March 2006, standard 12-lead
ECG monitoring was used during ajmaline provocation.
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Risk Factors in Brugada Syndrome June 7, 2011:2340–5Subsequently, further “high” right ventricular leads were
added to improve diagnostic yield by using a 15-lead ECG
recording machine. Initially, this technique used V1, V2, and
3 cranially displaced by 1 intercostal space (16) in addition
to the standard 12 conventional leads. In September 2009,
the standard V3 position was sacrificed in favor of including
1 and V2 cranially displaced in both the second and third
ntercostal spaces, in addition to conventional V1 and V2,
thereby maintaining 6 right ventricular leads for diagnostic
purposes. Diagnosis of a Brugada type 1 ECG pattern,
either during peak ajmaline effect or at baseline, was
established by ECG review by 2 investigators (H.R. and
M.P.). Any individual’s diagnosis of BrS was established as
described in the Definitions section.
Characteristics of SADS probands. Prior familial SCD
and presence of symptomatic events in each proband were
determined by interviews with all evaluated family members
by at least 1 of the investigators (H.R., M.P., S.S., and
E.R.B.) and review of medical examiner and coroner re-
ports. Structured clinical questions regarding the presence of
prior transient loss of consciousness, seizures, or faints were
retrospectively coded as probable syncopal events for the
study analysis. All decisions regarding relevance of symp-
toms described were made by 2 investigators (H.R. and
M.P.), with disputed results adjudicated by a senior inves-
tigator (E.R.B. or S.S.).
The presence of an antemortem ECG for all probands
was sought by detailed questioning of evaluated family
members. This included review of history of attendance at
health screening events, any hospital attendance, or presence
of any prior cardiovascular symptoms (palpitations or chest
pain) that may have prompted an ECG. When any family
members suggested the SADS proband may have attended
for medical assessment prior to his or her death, the
existence of an antemortem ECG was questioned by written
communication to any medical professional involved in the
proband’s investigation. As with familial ECGs, all ECGs
of probands taken before death were reviewed by 2 investi-
gators for evidence of a spontaneous Brugada pattern.
Definitions. SADS is an umbrella term for unexpected and
unexplained sudden death. It is characterized by the follow-
ing conditions: sudden death; age 1 to 64 years; last seen
alive and well within 12 h of being found dead; no prior
recorded cardiac disease; and normal coroner’s post-
mortem, negative toxicology results, and normal expert
cardiac pathologist’s examination, when available (17). A
proband represents any individual who experienced a SADS
death.
A type 1 Brugada ECG pattern is defined as 2-mm
coved-type ST elevation with or without right bundle
branch block pattern in at least 2 right precordial or “high”
right precordial (i.e., in the second or third intercostal space)
leads (18–21).
Familial diagnosis of BrS was established by the identi-
fication of spontaneous or ajmaline-provoked Brugada type
1 ECG pattern in any one family member of a SADSproband. The cause of death in the proband was presumed
to be BrS-related in all cases described, following a familial
diagnosis of BrS. When the familial SADS proband died at
age 45 years or older, the presence of other syndromic
diagnostic criteria, such as more than 1 family member with
typical Brugada ECG phenotype or syncopal symptoms,
was determined by additional structured questioning and
review of familial cardiological evaluation results.
Results
At least 1 member of a family group was diagnosed with
BrS in 49 families affected by a SADS death, suggesting
that BrS is the likely etiology for any associated proband’s
sudden death. A total of 50 probands were included, with 1
family having 2 individuals with confirmed SADS. In 2
families reviewed, the proband was older than 45 years. One
of these 2 families had stereotypical Brugada ECG changes
in more than 1 blood relative, thereby fulfilling the consen-
sus statement diagnostic criteria (1).
Demographics. Details of associated familial evaluation
are provided in Table 1. In total, 202 blood relatives of
probands were cardiologically evaluated and contributed to
the reported proband histories. Demographic characteristics
and reported symptoms in the included probands are sum-
marized in Table 2. The mean age of death of probands was
29.1  10.6 years (range 4 to 56 years). A predominance of
male BrS deaths was noted (41 male [82%] vs. 9 female
[18%]; p 0.05). Circumstances of death were obtained for
46 probands. Of these, 18 deaths (39%) occurred during
sleep, with a further 19 (41%) at rest during the daytime;
only 5 (11%) occurred during or immediately after signifi-
cant exertion.
Genetic testing. Details of families for whom SCN5A
mutation analysis was undertaken (n  28) are given in
Table 2. Of the 5 families with unequivocal mutations, 3
have mutations that have previously been reported as disease
causing (2 families with E1784K and 1 family with I1377V
mutations) and 2 have highly probable novel mutations
(D349H and H558fs). Overall, unequivocal mutations have
been found in 18% of families for whom SCN5A mutation
analysis was undertaken.
Risk profile of probands. Antemortem ECGs were avail-
able for 5 probands (Fig. 2), 1 of which demonstrated a
spontaneous type 1 pattern (Fig. 2A) and was taken during
presentation with gastrointestinal symptoms in a previously
asymptomatic individual. A further proband had evidence of
Breakdown of SADS Familial EvaluationTable 1 Breakdown of SADS Familial Evaluation
No. of Family
Members
Total evaluated 202
Mean no. evaluated per family  SD 4.0 2.4
Total diagnosed with BrS 83
Mean no. diagnosed with BrS per family  SD 1.7 1.1BrS  Brugada syndrome; SADS  sudden arrhythmic death syndrome.
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ventricular lead (Fig. 2B). Both of these ECGs were taken
more than 1 year before each proband’s terminal event.
None of the probands had undergone prior provocation
testing for investigation of inducible Brugada ECG pattern
or invasive electrophysiological assessment; none had a
pre-established personal or familial diagnosis of BrS or
other inherited cardiac disease. Probands’ symptoms before
death were reported reliably by family members in 45 cases,
with the remainder uncertain of any prior medical history or
symptoms. Only 9 of these 45 probands (20%) were
reported to have experienced at least 1 syncopal episode
before the fatal event. Seven probands (14%) had a prior
family history of premature SCD, 1 of whom also had a
personal history of syncope. Fifteen probands (30%) had
either a prior family history of SCD or personal reported
history of syncope. Among those who were previously
symptomatic, 5 probands were male, whereas 4 were female.
Discussion
We report on 50 individuals who experienced sudden death
related to BrS, who were diagnosed retrospectively follow-
ing careful cardiological evaluation of family members. In
keeping with previous reports, there was a male preponder-
ance among probands, a significant minority with identified
disease-causing familial SCN5A mutations, and deaths
occurring predominantly at rest or during sleep (3,12,22).
Markers of risk in BrS. Current data regarding prospective
risk stratification in patients with BrS have predominantly
been determined on the basis of short- and medium-term
prospective cohort observation of those identified in life.
The FINGER (France, Italy, the Netherlands, Germany)
study remains the largest cohort studied thus far, with 1,029
consecutive patients and indicates that a prior cardiac arrest,
spontaneous type 1 ECG, and syncope were the only
independent indicators of arrhythmic risk in patients with
Brugada ECG (13).
In our cohort of SADS probands with BrS, only 18%
(9 of 50) had a confirmed prior identified syncopal event, as
determined by reported symptoms and medical history from
Clinical Characteristics of SADS ProbandsW th Familial Diagnosi BrSTable 2 Clinical Characteristics of SADS ProbandsWith Familial Diagnosis of BrS
Clinical Presentation Syncope Asymptomatic Unknown
No. of probands 9 36 5
Male/female 5/4 31/5 5/0
Age, yrs 29 16 29 10 31 6
Type 1 BrS pattern/no. of ECGs
available
0/2 1/3 0/0
Family history of prior SCD 1 (11) 6 (17) 0 (0)
Died in sleep or rest 8 (89) 28 (78) 1 (20)
Definite mutation/SCN5A analysis 1/5 4/22 1/1
Values are n, mean  SD, or n (%).
ECG  electrocardiogram; SCD  sudden cardiac death; SCN5A  sodium channel, voltage-
gated, type V, alpha subunit; other abbreviations as in Table 1.relatives. This suggests that the majority of sudden deaths inFigure 2 Antemortem ECGs in 5 SADS Probands
With Brugada Syndrome
(A) The sole spontaneous type 1 antemortem ECG seen in our cohort of SADS
probands with BrS. (B) An antemortem borderline type 3 Brugada phenotype
seen in V2 only. (C) A nondiagnostic antemortem adult ECG. (D) An antemor-
tem ECG taken at age 8 years, with no spontaneous Brugada phenotype. (E)
An antemortem ECG taken at age 4 years, with no spontaneous Brugada phe-
notype. Abbreviations as in Figure 1.
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Risk Factors in Brugada Syndrome June 7, 2011:2340–5BrS occurred in asymptomatic individuals. The absence of
symptoms, however, does not necessarily ensure absence of
significant prior arrhythmia. Cohort observation of ICD
interrogations in 19 patients with BrS with prior aborted
sudden death revealed 64 episodes detected as ventricular
fibrillation, 26 of which were asymptomatic by virtue of
them being nocturnal and self-limiting, requiring no device
discharge (1). This evidently limits the sensitivity of
reported symptoms as a marker of prior ventricular
arrhythmias. Furthermore, the specificity of syncope for
ventricular arrhythmias among patients with BrS may be
limited by the observation that there is a preponderance
of other etiologies of syncope, including reports of
significant vasovagal responses with head-up tilt testing
among patients with BrS (23).
Although ECGs were available for a minority of pro-
bands, only 1 demonstrated a spontaneous type 1 pattern,
calling into question the utility of its absence as a marker of
low risk.
Of the total cohort, only 18% were identified as fulfilling
2005 consensus (1) criteria for ICD implantation on the
basis of prior syncope. A further 14% may have warranted
risk stratification with electrophysiological study according
to consensus criteria because of the presence of a type 1
ECG before death (1 of 50) or a family history of prior SCD
(6 of 50). Hence, current markers of risk for cardiac events
and sudden death would have been insensitive, with 68% of
our cohort categorized as low risk. Therefore, these markers
may not have predicted the BrS deaths, even if a diagnosis
of BrS had already been established. In particular, the
majority of our cohort was asymptomatic before unheralded
sudden death. Current data suggest that these asymptomatic
individuals’ risk would have been low, 1% per year (13),
ven if a spontaneous type 1 ECG pattern was seen. Given
hat current treatment is limited to ICD implantation, with
ts inherent complications in young patients, risk stratifica-
ion in asymptomatic patients clearly requires improvement.
ase inclusion. The diagnosis of BrS was based primarily
n the demonstration of a positive ajmaline provocation test
sing high right ventricular leads. Subsequent genetic eval-
ation of our cohort identified disease-causing SCN5A
utations in 18% of our included families. This figure is not
issimilar to that reported in previous genetic series in
atients with BrS and supports our diagnostic assumption
hat in the context of a death from SADS, a positive
jmaline provocation test using high right ventricular leads
s a genuine reflection of an underlying sodium ion channel
isorder (3). The utility of high right ventricular leads has
een confirmed in a few small series, predominantly in
outheast Asian patients (21,24,25). The 2005 Heart
hythm Society and European Heart Rhythm Association
onsensus document recommends that this group be treated
o differently than those with ECG changes in standard
eads (1).
tudy limitations. Despite being the largest cohort of its
ind reported, this study remains limited by the relativelymall number of SADS probands with BrS included. Only
probands had a documented prior ECG in this study.
ence, it is difficult to make judgments on the presence or
bsence of a spontaneous type 1 Brugada ECG in the
bsence of prior investigation. This is an important consid-
ration, given its apparent importance in risk stratification
1), although syncope is a much more significant risk factor
13). Unsurprisingly, in light of their predominantly asymp-
omatic status, none of the SADS probands had undergone
omprehensive cardiological evaluation before the terminal
vent. It is also possible that probands may not have relayed
ny prior symptoms to family members and medical
ractitioners.
onclusions
his cohort suggests that the majority of individuals expe-
iencing BrS sudden death are asymptomatic before their
erminal event. Antemortem ECGs, when available, do not
emonstrate a spontaneous type 1 ECG pattern. This
uggests that current risk factors in BrS are insufficient to
oretell unheralded sudden death events in those affected.
his questions the utility of current risk stratification
riteria.
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